%A Hao-jun ZHUANG, Mei-liang GUO, Wan-wen LIU, Hui DENG %T Clinical research progress of Janus kinase inhibitors in the treatment of atopic dermatitis %0 Journal Article %D 2021 %J Journal of Shanghai Jiao Tong University (Medical Science) %R 10.3969/j.issn.1674-8115.2021.07.019 %P 963-966 %V 41 %N 7 %U {https://xuebao.shsmu.edu.cn/CN/abstract/article_13115.shtml} %8 2021-07-28 %X

Atopic dermatitis is a chronic inflammatory skin disease, which is mainly related to changes in Th2 type signaling pathways. Increased expression of interleukin-4 (IL-4) and IL-13 reduces filaggrin, which leads to skin barrier defects. The Janus kinase-singal transducer and activator of transcriprion (Jak-STAT) signaling pathway is closely related to the pathogenesis of atopic dermatitis. Inhibiting the Jak-STAT signaling pathway is a potential method to treat atopic dermatitis. Janus kinase (JAK) inhibitors can be divided into first-generation and second-generation JAK inhibitors in the selection of JAKs′ inhibition. By summarizing the efficacy and safety of the first-generation and second-generation JAK inhibitors in clinical trials, the clinical research progress of JAK inhibitors in the treatment of atopic dermatitis is clarified.